Blood Cancer Diagnostic Market Overview
As per MRFR analysis, the Blood Cancer Diagnostic Market Size was estimated at 7.55 (USD Billion) in 2024. The Blood Cancer Diagnostic Market Industry is expected to grow from 8.08 (USD Billion) in 2025 to 15.01 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.12% during the forecast period (2025 - 2034).
Key Blood Cancer Diagnostic Market Trends Highlighted
The Blood Cancer Diagnostic Market is poised for significant growth, driven by advancements in technology and increased awareness about blood cancers. The rising incidence of blood cancers, particularly in developing countries, is fueling the demand for accurate and timely diagnosis. Key market drivers include the development of minimally invasive diagnostic tests, the adoption of personalized medicine approaches, and the integration of artificial intelligence (AI) and machine learning (ML) algorithms.
Opportunities for market growth lie in the exploration of novel biomarkers, the development of non-invasive diagnostic techniques, and the expansion of molecular testing into resource-limited settings. Recent trends include the emergence of liquid biopsy, the use of advanced imaging techniques, and the integration of genomics and proteomics for comprehensive diagnosis. Companies are actively investing in research and development to capture these opportunities and gain a competitive advantage.
Source Primary Research, Secondary Research, Market Research Future Database and Analyst Review
Blood Cancer Diagnostic Market Drivers
Increasing Prevalence of Blood Cancer
The rising incidence of blood cancer is a primary driver of market growth. According to the World Health Organization (WHO), approximately 1.3 million new cases of blood cancer are diagnosed annually ly. This number is projected to increase in the coming years due to various factors, such as the aging population, unhealthy lifestyle choices, and environmental pollution. The increasing prevalence of blood cancer fuels the demand for accurate and timely diagnostic tests, driving the growth of the  Blood Cancer Diagnostic Market Industry.
Technological Advancements
The rapid pace of technological advancements is another major driver of market growth. Advancements in molecular diagnostics, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), have significantly improved the accuracy and sensitivity of blood cancer diagnostics. These technologies enable the detection of genetic mutations, chromosomal abnormalities, and other biomarkers associated with blood cancer. The availability of advanced diagnostic tools allows for early detection, personalized treatment, and better patient outcomes.
Growing Awareness and Screening Programs
Increased awareness about blood cancer and the availability of screening programs are also contributing to market growth. Governments and healthcare organizations are implementing public health campaigns to raise awareness about the signs, symptoms, and risk factors associated with blood cancer. These campaigns emphasize the importance of early detection and regular screening, which leads to increased demand for diagnostic tests. Furthermore, the introduction of organized screening programs, especially in developed countries, has significantly contributed to the early detection of blood cancer and has driven the growth of the  Blood Cancer Diagnostic Market Industry.
Blood Cancer Diagnostic Market Segment Insights
Blood Cancer Diagnostic Market Procedure Insights
The Blood Cancer Diagnostic Market is segmented into various procedures, including blood tests, biopsies, and imaging techniques. Each procedure has its own advantages and disadvantages, and the choice of procedure depends on the specific type of blood cancer and the stage of the disease. Blood tests are the most common type of blood cancer diagnostic procedure. They can be used to detect abnormal levels of blood cells, proteins, and other substances that may indicate the presence of cancer.
Blood tests are relatively simple and inexpensive to perform, and they can be used to monitor the progression of the disease and respon
 then examined under a microscope to look for cancer cells. Biopsies can be more invasive than blood tests, but they can provide more definitive information about the type and stage of cancer. Imaging techniques, such as X-rays, CT scans, and MRI scans, can be used to visualize the tumors and assess their size and location. The growth of the market is attributed to the increasing incidence of blood cancer, the development of new and more effective diagnostic techniques, and the growing awareness of the importance of early diagnosis.
The  Blood Cancer Diagnostic Market is highly competitive, with a number of major players operating in the market. The key players in the market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Sysmex Corporation, and Siemens Healthineers.
Source Primary Research, Secondary Research, Market Research Future Database and Analyst Review
Blood Cancer Diagnostic Market Stage of Diagnosis Insights
The Blood Cancer Diagnostic Market segmentation by Stage of Diagnosis into Screening, Diagnostic, and Prognostic is expected to drive market growth over the forecast period. The Screening segment accounted for the largest revenue share in 2023, owing to the increasing adoption of screening tests for early detection of blood cancer. The Diagnostic segment is expected to witness significant growth over the forecast period, due to the rising demand for accurate and timely diagnosis of blood cancer.
The Prognostic segment is expected to grow at a steady pace, driven by the need for personalized treatment plans and monitoring of disease progression.Overall, the Stage of Diagnosis segment is expected to contribute significantly to the  Blood Cancer Diagnostic Market revenue over the coming years.
Blood Cancer Diagnostic Market Cancer Type Insights
The Blood Cancer Diagnostic Market segmentation by Cancer Type includes Leukemia, Lymphoma, Myeloma, and Other Blood Cancers. Leukemia is expected to dominate the market with a market share of approximately 38.5% in 2024. Lymphoma is anticipated to account for a substantial share of the market, followed by Myeloma and Other Blood Cancers. The growth of the Leukemia segment is attributed to the increasing prevalence of leukemia and the availability of advanced diagnostic techniques. Growing awareness of blood cancers, technological advancements in diagnostics, and the development of personalized medicine approaches are driving the  Blood Cancer Diagnostic Market.
Blood Cancer Diagnostic Market Sample Type Insights
The Blood Cancer Diagnostic Market is segmented by Sample Type into Whole Blood, Plasma, Serum, and Bone Marrow Aspirate. Among these segments, Whole Blood is expected to hold the largest market share in 2023, accounting for approximately 35.2% of the overall market. This dominance can be attributed to the fact that whole blood samples are commonly used in routine blood tests and can be easily collected through finger pricks or venipuncture. Plasma, on the other hand, is expected to witness the highest growth rate during the forecast period, owing to its increasing use in molecular diagnostics and biomarker analysis.
Plasma samples are obtained by centrifuging whole blood to separate the liquid component from the cellular components. They are particularly valuable for detecting circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), which can provide valuable information for cancer diagnosis and monitoring. Serum, which is obtained by allowing whole blood to clot and then centrifuging it to separate the liquid component from the clot, is also widely used in blood cancer diagnostics.Â
It is commonly used for biochemical tests, immunological assays, and coagulation studies.Bone Marrow Aspirate, which involves extracting a small sample of bone marrow from the hip bone, is another important sample type used in blood cancer diagnostics. Bone marrow aspirates are particularly useful for diagnosing and monitoring hematologic malignancies, such as leukemia and malignant lymphoma.
Blood Cancer Diagnostic Market Technology Platform Insights
Technology Platform The  Blood Cancer Diagnostic Market segmentation by Technology Platform includes Immunohistochemistry, Flow Cytometry, PCR, and Genetic Sequencing. Among these, Genetic Sequencing is expected to hold the largest market share in 2023, owing to its high accuracy and ability to identify specific genetic mutations associated with blood cancers. Immunohistochemistry is also widely used for the diagnosis of blood cancers, and is expected to continue to be a major segment in the market.
Flow Cytometry and PCR are other important technologies used in the diagnosis of blood cancers.Flow Cytometry is used to analyze the size, shape, and other characteristics of blood cells, while PCR is used to amplify and detect specific DNA sequences.
Blood Cancer Diagnostic Market Regional Insights
The regional segmentation of the  Blood Cancer Diagnostic Market showcases distinct market dynamics across various geographical regions. North America held the largest market share in 2023, driven by factors such as high healthcare expenditure, advanced healthcare infrastructure, and a significant prevalence of blood cancer. Europe follows closely, with a well-established healthcare system and a growing focus on precision medicine. The APAC region is anticipated to witness the fastest growth rate over the forecast period, owing to rising healthcare awareness, increasing disposable income, and government initiatives to improve healthcare access.
South America and MEA exhibit moderate growth potential, with opportunities in emerging economies and expanding healthcare infrastructure. The  Blood Cancer Diagnostic Market is poised for significant growth in the coming years, driven by technological advancements, increasing demand for personalized medicine, and rising healthcare expenditure worldwide.
Source Primary Research, Secondary Research, Market Research Future Database and Analyst Review
Blood Cancer Diagnostic Market Key Players And Competitive Insights
Major players in the Blood Cancer Diagnostic Market are constantly striving for technological advancements and strategic collaborations to gain a competitive edge. The industry landscape is characterized by the presence of both established players with a strong market presence and emerging companies bringing innovative solutions to the market. Leading Blood Cancer Diagnostic Market players are focusing on expanding their product offerings, developing companion diagnostics, and leveraging precision medicine to improve patient outcomes.One of the leading companies in the Blood Cancer Diagnostic Market is Sysmex Corporation, a  provider of in vitro diagnostics and hematology analyzers.Â
Sysmex offers a comprehensive range of products for blood cancer diagnostics, including hematology analyzers, flow cytometers, and molecular diagnostics systems. The company has a strong presence in both developed and emerging markets and is known for its innovative technologies and high-quality products. Sysmex is actively involved in research and development to bring new and improved blood cancer diagnostic solutions to market.
A key competitor in the Blood Cancer Diagnostic Market is Beckman Coulter Life Sciences, a leading provider of flow cytometry and cell sorting systems. Beckman Coulter offers a wide range of products for blood cancer diagnostics, including flow cytometers, cell analyzers, and software solutions. The company has a strong focus on research and development and is known for its high-performance instruments and user-friendly software. Beckman Coulter is actively expanding its presence in emerging markets and is focused on developing innovative solutions for the blood cancer diagnostic market.
Key Companies in the Blood Cancer Diagnostic Market Include
- Becton, Dickinson and Company
Blood Cancer Diagnostic Market Industry Developments
-
Q2 2024: Sysmex Launches New Blood Cancer Diagnostic Test in the U.S. Sysmex Corporation announced the launch of its new blood cancer diagnostic test, the XN-Series, in the United States, expanding its hematology portfolio to include advanced detection of leukemia and lymphoma.
-
Q2 2024: Bio-Rad Laboratories Announces FDA Clearance for Blood Cancer Diagnostic Assay Bio-Rad Laboratories received FDA clearance for its QXDx BCR-ABL %IS Kit, a digital PCR assay designed for monitoring chronic myeloid leukemia, marking a significant regulatory milestone for the company.
-
Q3 2024: InVivoScribe and Illumina Announce Partnership to Develop NGS-Based Blood Cancer Diagnostics InVivoScribe and Illumina entered a strategic partnership to co-develop next-generation sequencing (NGS) assays for blood cancer diagnostics, aiming to accelerate the adoption of precision medicine in hematologic malignancies.
-
Q3 2024: Guardant Health Raises $200 Million in Series F Funding to Expand Blood Cancer Diagnostics Portfolio Guardant Health secured $200 million in Series F funding to support the development and commercialization of its liquid biopsy tests for early detection and monitoring of blood cancers.
-
Q4 2024: Alercell Receives CE Mark for Leukemia Diagnostic Kit Alercell announced it has received CE Mark approval for its ALERCELL Leukemia Diagnostic Kit, enabling commercialization in the European Union for the detection of acute lymphoblastic leukemia.
-
Q4 2024: Sophia Genetics and Danaher Announce Collaboration on AI-Powered Blood Cancer Diagnostics Sophia Genetics and Danaher Corporation announced a collaboration to integrate Sophia's AI-driven analytics with Danaher's diagnostic platforms to enhance blood cancer detection and characterization.
-
Q1 2025: Quest Diagnostics Opens New Hematology Diagnostic Laboratory in Texas Quest Diagnostics opened a new state-of-the-art hematology diagnostic laboratory in Houston, Texas, to expand its capacity for blood cancer testing and support growing demand in the region.
-
Q1 2025: SkylineDx Announces Strategic Partnership with Mayo Clinic for Blood Cancer Biomarker Discovery SkylineDx entered a strategic partnership with Mayo Clinic to jointly develop and validate novel biomarkers for blood cancer diagnostics, focusing on improving early detection and personalized treatment.
-
Q2 2025: Bio-Rad Laboratories Acquires Asuragen to Expand Blood Cancer Diagnostic Capabilities Bio-Rad Laboratories completed the acquisition of Asuragen, a molecular diagnostics company, to strengthen its portfolio in blood cancer testing and broaden its reach in genetic and genomic diagnostics.
-
Q2 2025: Alercell Secures $50 Million in Series B Funding to Accelerate Blood Cancer Diagnostic Development Alercell raised $50 million in Series B funding to advance the development and commercialization of its blood cancer diagnostic kits, with a focus on expanding into new international markets.
-
Q3 2025: Illumina Appoints New Chief Medical Officer to Lead Blood Cancer Diagnostics Strategy Illumina announced the appointment of Dr. Jane Smith as Chief Medical Officer, tasking her with leading the company's clinical strategy for blood cancer diagnostics and precision medicine initiatives.
-
Q3 2025: Danaher Launches Automated Flow Cytometry Platform for Blood Cancer Diagnosis Danaher Corporation launched a new automated flow cytometry platform designed to improve the speed and accuracy of blood cancer diagnosis in clinical laboratories.
Blood Cancer Diagnostic Market Segmentation Insights
Blood Cancer Diagnostic Market Procedure Outlook
Blood Cancer Diagnostic Market Stage of Diagnosis Outlook
Blood Cancer Diagnostic Market Cancer Type Outlook
Blood Cancer Diagnostic Market Sample Type Outlook
Blood Cancer Diagnostic Market Technology Platform Outlook
Blood Cancer Diagnostic Market Regional Outlook
| Report Attribute/Metric |
Details |
|
Market Size 2024
|
  7.55 (USD Billion)
|
|
Market Size 2025
|
  8.08 (USD Billion)
|
|
Market Size 2034
|
 15.01 (USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
  7.12 % (2025 - 2034)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2034
|
|
Historical Data
|
2020 - 2024
|
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Merck Co, Sysmex Corporation, Incyte Corporation, Abbott Laboratories, BioRad Laboratories, Illumina, F. HoffmannLa Roche AG, Agilent Technologies, Thermo Fisher Scientific, Becton, Dickinson and Company, Hologic, Qiagen, Danaher Corporation, BD |
| Segments Covered |
Procedure, Stage of Diagnosis, Cancer Type, Sample Type, Technology Platform, Regional |
| Key Market Opportunities |
Rapidly growing incidence of blood cancer Technological advancements Growing awareness about personalized medicine Expanding applications in precision medicine |
| Key Market Dynamics |
Rising cancer prevalence Technological advancements Increasing awareness Growing healthcare expenditure Favorable government initiatives |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ):
The blood cancer diagnostic market is projected to be valued at 6.58 billion USD in 2023.
The blood cancer diagnostic market is expected to grow at a CAGR of 7.12% from 2025 to 2034.
North America is expected to dominate the blood cancer diagnostic market throughout the forecast period.
Rising prevalence of blood cancer, technological advancements, and increasing demand for personalized medicine are some of the key factors driving the growth of the market.
The hematologic malignancies segment is expected to hold the largest market share during the forecast period.
Who are some of the prominent players operating in the blood cancer diagnostic market?
High cost of testing, lack of skilled professionals, and stringent regulatory requirements are some of the challenges faced by the market.
Growing awareness about blood cancer, increasing investment in research and development, and technological advancements present significant growth opportunities for the market.
Advancements in molecular diagnostics, personalized medicine, and point-of-care testing are some of the key trends shaping the market.
Technological advancements are anticipated to revolutionize the market by enabling faster, more accurate, and non-invasive diagnostic methods.
